Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	CA$0.1350	-3.57%	547,514
10/09/26	CA$0.1400	0.00%	500,864
09/09/26	CA$0.1400	+7.69%	350,479
08/09/26	CA$0.1300	+18.18%	1,440,931
04/09/26	CA$0.1100	-4.35%	65,264

End-of-day quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1350CAD

Average target price

1.000CAD

Spread / Average Target

+640.74%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

End-of-day quote Toronto S.E. 11/09/2026			5-day change	1st Jan Change
0.1350 ^CAD	-3.57%		+22.73%	+3.85%

09-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09-08	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI

Market Cap	50.98M 36.75M 31.66M 29.98M 27.17M 3.51B 51.24M 356M 137M 1.79B 138M 135M 5.64B	P/E 2026 *	-5.4x	P/E 2027 *	-4.5x
Enterprise Value	50.98M 36.75M 31.66M 29.98M 27.17M 3.51B 51.24M 356M 137M 1.79B 138M 135M 5.64B	EV / Sales 2026 *	-	EV / Sales 2027 *	20.4x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
Toronto S.E.	SVA	Delayed
OTC Markets	SEOVF	Delayed
Tradegate	PSH0	Real-time
Xetra	PSH0	Delayed
Deutsche Boerse AG	PSH0	Delayed
Börse Stuttgart	PSH0	Delayed
Boerse Muenchen	PSH0	Real-time

09-11	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
09-08	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI
06-17	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
06-12	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
04-23	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
03-14	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
03-04	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
12-20	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
12-19	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
11-13	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
23/09/25	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
15/09/25	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
09/07/25	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT

Sernova Biotherapeutics Inc Stock

Stocks

SVA

CA81752F1062

Medical Equipment, Supplies & Distribution

Valuation : Sernova Biotherapeutics Inc

Chart: Sernova Biotherapeutics Inc

Latest news : Sernova Biotherapeutics Inc

Press Releases : Sernova Biotherapeutics Inc

News in other languages : Sernova Biotherapeutics Inc

Quotes and Performance

Price Extremes

Managers and Directors : Sernova Biotherapeutics Inc

Latest insider transactions

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

09-12	Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.	NE
09-10	Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference	AQ
09-08	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ
07-21	A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up	AQ
06-17	Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy	AQ

15/09/23	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
13/09/23	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
03/05/23	AstraZeneca : accord de recherche avec le canadien Sernova
03/05/23	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
10/04/23	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

1 day	-3.57%
1 week	+22.73%
Current month	+22.73%
1 month	+22.73%
3 months	-12.90%
6 months	-20.59%
Current year	+3.85%

1 week	0.1	0.15
1 month	0.1	0.15
Current year	0.1	0.2
1 year	0.1	0.2
3 years	0.1	0.83
5 years	0.1	2.22
10 years	0.1	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	58	12/08/2024
James Parsons DFI	Director of Finance/CFO	60	11/10/2024
David Burke IRC	Investor Relations Contact	-	11/10/2024

Director	Title	Age	Since
James Parsons BRD	Director/Board Member	60	19/04/2012
Steven Sangha BRD	Director/Board Member	-	24/04/2023
David Paterson BRD	Director/Board Member	-	01/09/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
03/07/26	SERNOVA BIOTHERAPEUTICS, INC.	Sell	Company	-115,000	0.0305%
22/05/26	John Brooks	Option	Chairman	228,912	0.0658%
22/05/26	Steven Sangha	Option	Director	260,000	0.0748%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA BIOTHERAPEUTICS INC	-3.57%	+22.73%	-27.03%	-82.91%	36.75M
STRYKER CORPORATION	+2.06%	-9.10%	-29.12%	-8.06%	106B
SMITH & NEPHEW PLC	-1.66%	-5.22%	-29.15%	-5.53%	11.47B
GLAUKOS CORPORATION	-1.84%	-5.76%	+91.21%	+120.15%	9.86B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-1.34%	-6.25%	-56.39%	-72.36%	3.94B
DOUBLE MEDICAL TECHNOLOGY INC.	-2.84%	-6.11%	-30.69%	+24.92%	2.33B
INSPIRE MEDICAL SYSTEMS, INC.	+7.16%	+15.73%	-11.84%	-67.34%	2.11B
INSIGHT LIFETECH CO., LTD.	+1.47%	-5.12%	-	-	1.84B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-2.10%	-4.52%	-24.89%	-31.67%	1.5B
Average	-0.30%	-0.15%	-14.74%	-15.35%	15.42B
Weighted average by Cap.	+1.32%	-7.88%	-20.96%	-1.10%

	2026 *	2027 *
Net sales	-	2.5M 1.8M 1.55M 1.47M 1.33M 172M 2.51M 17.46M 6.71M 87.59M 6.77M 6.62M 277M
Net income	-11.3M -8.15M -7.02M -6.65M -6.02M -778M -11.36M -78.92M -30.35M -396M -30.59M -29.92M -1.25B	-13.9M -10.02M -8.63M -8.17M -7.41M -957M -13.97M -97.08M -37.33M -487M -37.63M -36.8M -1.54B
Net Debt	-	-